SARM
GSK-2849466
SaveA tissue-selective androgen receptor modulator from GlaxoSmithKline's SARM program, evaluated in early clinical development for androgen-deficiency states.
Quick verdict
Limited publicly available data. Appears to have been discontinued in early development.
Evidence score
18/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Part of GSK's broader SARM pipeline. Minimal published preclinical or clinical data beyond early patent filings and conference abstracts.
Benefits
- Part of a major pharmaceutical SARM research program
- Designed for tissue selectivity
Dosage notes
No dosing information available.
Side effects
- Unknown in humans
Who should be cautious
Not approved for any use. Negligible public safety data.
What this page cannot tell you
Insufficient published evidence to draw meaningful conclusions about efficacy or safety.
Leaderboard scores
- Muscle20
Write a review
Sign in to write a review.